Parichat Uea-Areewongsa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Parichat Uea-Areewongsa has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Porntip Intapiboon
Allergy and Rheumatology Unit, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand
2 shared publications - Siriporn Juthong
Allergy and Rheumatology Unit, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand
2 shared publications - Boonjing Siripaitoon
Allergy and Rheumatology Unit, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand
1 shared publication - Boonjing Siripaitoon
Allergy and Rheumatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, HatYai, Thailand
1 shared publication - Jomkwan Ongarj
Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand
1 shared publication - Nawamin Pinpathomrat
Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand
1 shared publication
Latest Publications
- Open Access
- 28 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3913
Distinct Cytokine Profiles in Lupus Low Disease Activity State Subgroups Identify Patients at Risk for Disease Flare
We compared the cytokine profiles between two lupus low disease activity state (LLDAS) subgroups—clinically active (CA) and serologically active clinically quiescent (SACQ)—and identified predictors of disease flare. Fifty patients with systemic lupus erythematosus (25 CA, 25 SACQ) who maintained LLDAS for ≥6 months were enrolled and followed for 6 months. Cytokine modules were identified using weighted gene co-expression network analysis, and correlations with clinical traits were assessed. Predictors of flare were assessed using Cox regression. Three cytokine modules were identified. The brown (MCP-1 and IL-8) and turquoise (IFN-α, IFN-γ, IL-17A, IL-10, IL-12p70, IL-18, IL-23A, and IL-33) modules correlated with mucocutaneous and physician global assessment, respectively. These modules showed a positive, but not significant, correlation with CA. The comparison analysis revealed that IL-6 and IL-8 were higher in CA than in SACQ. Nine patients (18%) flared, six of whom belonged to the CA group. Flares were associated with a lower sustained LLDAS rate (77.8% vs. 34.1%) and higher levels of IL-1β, IL-6, and IL-33. In multivariable analysis, non-sustained LLDAS (HR 8.73) and IL-6 ≥ 45.1 pg/mL (HR 10.4) independently predicted a flare. Our study demonstrated that cytokine elevation persists despite LLDAS. Non-sustained LLDAS and elevated IL-6 predict a flare, suggesting that IL-6 may enhance the flare prediction biomarker.
- 28 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3913
Open AccessDistinct Cytokine Profiles in Lupus Low Disease Activity State Subgroups Identify Patients at Risk for Disease Flare
We compared the cytokine profiles between two lupus low disease activity state (LLDAS) subgroups—clinically active (CA) and serologically active clinically quiescent (SACQ)—and identified predictors of disease flare. Fifty patients with systemic lupus erythematosus (25 CA, 25 SACQ) who maintained LLDAS for ≥6 months were enrolled and followed for 6 months. Cytokine modules were identified using weighted gene co-expression network analysis, and correlations with clinical traits were assessed. Predictors of flare were assessed using Cox regression. Three cytokine modules were identified. The brown (MCP-1 and IL-8) and turquoise (IFN-α, IFN-γ, IL-17A, IL-10, IL-12p70, IL-18, IL-23A, and IL-33) modules correlated with mucocutaneous and physician global assessment, respectively. These modules showed a positive, but not significant, correlation with CA. The comparison analysis revealed that IL-6 and IL-8 were higher in CA than in SACQ. Nine patients (18%) flared, six of whom belonged to the CA group. Flares were associated with a lower sustained LLDAS rate (77.8% vs. 34.1%) and higher levels of IL-1β, IL-6, and IL-33. In multivariable analysis, non-sustained LLDAS (HR 8.73) and IL-6 ≥ 45.1 pg/mL (HR 10.4) independently predicted a flare. Our study demonstrated that cytokine elevation persists despite LLDAS. Non-sustained LLDAS and elevated IL-6 predict a flare, suggesting that IL-6 may enhance the flare prediction biomarker.
- Open Access
Humoral Immunogenicity of mRNA Booster Vaccination after Heterologous CoronaVac-ChAdOx1 nCoV-19 or Homologous ChAdOx1 nCoV-19 Vaccination in Patients with Autoimmune Rheumatic Diseases: A Preliminary Report
Immunogenicity data on the mRNA SARS-CoV-2 vaccine booster after completing a primary series vaccination, other than the mRNA vaccine, in patients with autoimmune rheumatic diseases (ARDs) is scarce. In this study, we reported the humoral immunogenicity of an mRNA booster 90–180 days after completing heterologous CoronaVac/ChAdOx1 nCoV-19 (n = 19) or homologous ChAdOx1 nCoV-19 (n = 14) vaccination by measuring the anti-SARS-CoV-2 receptor binding domain (RBD) IgG levels at one and three months after mRNA booster vaccination. This study included 33 patients with ARDs [78.8% women; mean (SD) age: 42.9 (10.6) years]. Most patients received prednisolone (75.8%, mean [IQR] daily dose: 7.5 [5, 7.5] mg) and azathioprine (45.5%). The seropositivity rates were 100% and 92.9% in CoronaVac/ChAdOx1 and ChAdOx1/ChAdOx1, respectively. The median (IQR) anti-RBD IgG level was lower in the ChAdOx1/ChAdOx1 group than in the CoronaVac/ChAdOx1 group (1867.8 [591.6, 2548.6] vs. 3735.8 [2347.9, 5014.0] BAU/mL, p = 0.061). A similar trend was significant in the third month [597.8 (735.5) vs. 1609.9 (828.4) BAU/mL, p = 0.003]. Minor disease flare-ups occurred in 18.2% of the patients. Our findings demonstrated satisfactory humoral immunogenicity of mRNA vaccine boosters after a primary series, with vaccine strategies other than the mRNA platform. Notably, the vaccine-induced immunity was lower in the ChAdOx1/ChAdOx1 primary series.
Open AccessHumoral Immunogenicity of mRNA Booster Vaccination after Heterologous CoronaVac-ChAdOx1 nCoV-19 or Homologous ChAdOx1 nCoV-19 Vaccination in Patients with Autoimmune Rheumatic Diseases: A Preliminary Report
Immunogenicity data on the mRNA SARS-CoV-2 vaccine booster after completing a primary series vaccination, other than the mRNA vaccine, in patients with autoimmune rheumatic diseases (ARDs) is scarce. In this study, we reported the humoral immunogenicity of an mRNA booster 90–180 days after completing heterologous CoronaVac/ChAdOx1 nCoV-19 (n = 19) or homologous ChAdOx1 nCoV-19 (n = 14) vaccination by measuring the anti-SARS-CoV-2 receptor binding domain (RBD) IgG levels at one and three months after mRNA booster vaccination. This study included 33 patients with ARDs [78.8% women; mean (SD) age: 42.9 (10.6) years]. Most patients received prednisolone (75.8%, mean [IQR] daily dose: 7.5 [5, 7.5] mg) and azathioprine (45.5%). The seropositivity rates were 100% and 92.9% in CoronaVac/ChAdOx1 and ChAdOx1/ChAdOx1, respectively. The median (IQR) anti-RBD IgG level was lower in the ChAdOx1/ChAdOx1 group than in the CoronaVac/ChAdOx1 group (1867.8 [591.6, 2548.6] vs. 3735.8 [2347.9, 5014.0] BAU/mL, p = 0.061). A similar trend was significant in the third month [597.8 (735.5) vs. 1609.9 (828.4) BAU/mL, p = 0.003]. Minor disease flare-ups occurred in 18.2% of the patients. Our findings demonstrated satisfactory humoral immunogenicity of mRNA vaccine boosters after a primary series, with vaccine strategies other than the mRNA platform. Notably, the vaccine-induced immunity was lower in the ChAdOx1/ChAdOx1 primary series.